125 related articles for article (PubMed ID: 29683434)
1. Tandem bispecific broadly neutralizing antibody - a novel approach to HIV-1 treatment.
Ferrari G
J Clin Invest; 2018 Jun; 128(6):2189-2191. PubMed ID: 29683434
[TBL] [Abstract][Full Text] [Related]
2. Tandem bispecific neutralizing antibody eliminates HIV-1 infection in humanized mice.
Wu X; Guo J; Niu M; An M; Liu L; Wang H; Jin X; Zhang Q; Lam KS; Wu T; Wang H; Wang Q; Du Y; Li J; Cheng L; Tang HY; Shang H; Zhang L; Zhou P; Chen Z
J Clin Invest; 2018 Jun; 128(6):2239-2251. PubMed ID: 29461979
[TBL] [Abstract][Full Text] [Related]
3. Tandem bispecific antibody prevents pathogenic SHIV
Niu M; Wong YC; Wang H; Li X; Chan CY; Zhang Q; Ling L; Cheng L; Wang R; Du Y; Yim LY; Jin X; Zhang H; Zhang L; Chen Z
Cell Rep; 2021 Aug; 36(8):109611. PubMed ID: 34433029
[TBL] [Abstract][Full Text] [Related]
4. Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs.
Brozy J; Schlaepfer E; Mueller CKS; Rochat MA; Rampini SK; Myburgh R; Raum T; Kufer P; Baeuerle PA; Muenz M; Speck RF
J Virol; 2018 Jul; 92(14):. PubMed ID: 29720517
[TBL] [Abstract][Full Text] [Related]
5. Targeting the HIV-1 Spike and Coreceptor with Bi- and Trispecific Antibodies for Single-Component Broad Inhibition of Entry.
Khan SN; Sok D; Tran K; Movsesyan A; Dubrovskaya V; Burton DR; Wyatt RT
J Virol; 2018 Sep; 92(18):. PubMed ID: 29976677
[TBL] [Abstract][Full Text] [Related]
6. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 bispecific antibody iMab-N6 exhibits enhanced breadth but not potency over its parental antibodies iMab and N6.
Moshoette T; Papathanasopoulos MA; Killick MA
Virol J; 2022 Sep; 19(1):143. PubMed ID: 36071449
[TBL] [Abstract][Full Text] [Related]
8. Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies.
Zhang Z; Li S; Gu Y; Xia N
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869733
[TBL] [Abstract][Full Text] [Related]
9. Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity.
Huang Y; Yu J; Lanzi A; Yao X; Andrews CD; Tsai L; Gajjar MR; Sun M; Seaman MS; Padte NN; Ho DD
Cell; 2016 Jun; 165(7):1621-1631. PubMed ID: 27315479
[TBL] [Abstract][Full Text] [Related]
10. Bispecific Antibodies Against HIV.
Montefiori DC
Cell; 2016 Jun; 165(7):1563-1564. PubMed ID: 27315470
[TBL] [Abstract][Full Text] [Related]
11. Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection.
Cohen YZ; Caskey M
Curr Opin HIV AIDS; 2018 Jul; 13(4):366-373. PubMed ID: 29697469
[TBL] [Abstract][Full Text] [Related]
12. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes.
Ditse Z; Muenchhoff M; Adland E; Jooste P; Goulder P; Moore PL; Morris L
J Virol; 2018 Sep; 92(17):. PubMed ID: 29950423
[TBL] [Abstract][Full Text] [Related]
15. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes.
Kong R; Louder MK; Wagh K; Bailer RT; deCamp A; Greene K; Gao H; Taft JD; Gazumyan A; Liu C; Nussenzweig MC; Korber B; Montefiori DC; Mascola JR
J Virol; 2015 Mar; 89(5):2659-71. PubMed ID: 25520506
[TBL] [Abstract][Full Text] [Related]
16. Broadly neutralizing antibody and the HIV reservoir in acute HIV infection: a strategy toward HIV remission?
Ananworanich J; McSteen B; Robb ML
Curr Opin HIV AIDS; 2015 May; 10(3):198-206. PubMed ID: 25700203
[TBL] [Abstract][Full Text] [Related]
17. Towards HIV-1 remission: potential roles for broadly neutralizing antibodies.
Halper-Stromberg A; Nussenzweig MC
J Clin Invest; 2016 Feb; 126(2):415-23. PubMed ID: 26752643
[TBL] [Abstract][Full Text] [Related]
18. Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies.
Cheeseman HM; Olejniczak NJ; Rogers PM; Evans AB; King DFL; Ziprin P; Liao HX; Haynes BF; Shattock RJ
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795431
[TBL] [Abstract][Full Text] [Related]
19. [Trispecific broadly neutralizing antibodies for HIV immunoprophylaxis and immunotherapy?].
Barin F; Stefic K
Med Sci (Paris); 2018 Feb; 34(2):109-111. PubMed ID: 29451475
[No Abstract] [Full Text] [Related]
20. Tracing HIV-1 strains that imprint broadly neutralizing antibody responses.
Kouyos RD; Rusert P; Kadelka C; Huber M; Marzel A; Ebner H; Schanz M; Liechti T; Friedrich N; Braun DL; Scherrer AU; Weber J; Uhr T; Baumann NS; Leemann C; Kuster H; Chave JP; Cavassini M; Bernasconi E; Hoffmann M; Calmy A; Battegay M; Rauch A; Yerly S; Aubert V; Klimkait T; Böni J; Metzner KJ; Günthard HF; Trkola A;
Nature; 2018 Sep; 561(7723):406-410. PubMed ID: 30202088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
